Flag of the European Union EU Clinical Trials Register Help

Clinical trials for dendritic cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    31 result(s) found for: dendritic cells. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-007847-28 Sponsor Protocol Number: DERMA-ER-DC08 Start Date*: 2011-09-16
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: A multicenter, randomized, two-armed, open-label Phase III study to evaluate the adjuvant vaccination with tumor RNA-loaded autologous Dendritic Cells versus observation of patients with resected m...
    Medical condition: Patients with resected uveal melanoma showing monosomy 3, free of metastases
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10030052 Ocular melanomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000578-31 Sponsor Protocol Number: Rostock-Benralizumab-2018-1 Start Date*: 2018-07-05
    Sponsor Name:University Medicine Rostock
    Full Title: Impact of benralizumab treatment on circulating dendritic cells in patients with eosinophilic asthma
    Medical condition: Eosinophilic Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006962-41 Sponsor Protocol Number: CSTI571ADE60 Start Date*: 2008-03-27
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Dendritic cells as autologous vaccine in patients with chronic myeloid leukemia
    Medical condition: Chronic myeloid leukemia is a malignant disease of the blood. Without therapy it has an unfavourable prognosis. Under first-line therapy with newer inhibitors of the thymidinkinase some few patien...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-007170-30 Sponsor Protocol Number: TUD-Psslan-031 Start Date*: 2008-06-03
    Sponsor Name:Technical University of Dresden, faculty of medicine
    Full Title: Untersuchung des Phänotyps und der Funktion proinflammatorischer dendritischer Zellen während einer Therapie der Psoriasis vulgaris mit einem TNFalpha Antagonisten Investigation of phenotype and f...
    Medical condition: Psoriasis vulgaris
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-000304-14 Sponsor Protocol Number: GlioVax Start Date*: 2018-03-06
    Sponsor Name:Heinrich-Heine-University Düsseldorf
    Full Title: Phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy in newly diagnosed glioblastoma
    Medical condition: newly diagnosed glioblastoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004557-24 Sponsor Protocol Number: UKM17_0056 Start Date*: 2019-07-29
    Sponsor Name:Westfälische Wilhelms-Universität Münster c/o Universitätsklinikum Münster, Geschäftsbereich Recht u. Drittmittel
    Full Title: Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-000709-10 Sponsor Protocol Number: UKM12_0026 Start Date*: 2014-12-19
    Sponsor Name:Universitätsklinikum Münster
    Full Title: Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003093-21 Sponsor Protocol Number: 20091977 Start Date*: Information not available in EudraCT
    Sponsor Name:Medical Department I
    Full Title: Influence of combined therapy of niacin and statins on stem cell mobilization and inflammatory parameters in patients suffering from coronary artery disease – randomized clinical study -
    Medical condition: Have stable coronary artery disease (i.e. no acute event like myocardial infarction or PTCA less then 3 months ago)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001474-25 Sponsor Protocol Number: SVM9122 Start Date*: 2012-01-02
    Sponsor Name:Klinik für Dermatologie, Venerologie und Allergologie; Charité - Universitätsmedizin Berlin
    Full Title: A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node disse...
    Medical condition: The trial is planned in a neo-adjuvant setting for a 4-weeks period in Melanoma patients with stage III. The stage is to be discovered by ultrasound and veriefied by fine needle punctere and cytology.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022677-34 Sponsor Protocol Number: EMR200109-619 Start Date*: 2011-09-07
    Sponsor Name:Dekan des Fachbereichs Humanmedizin
    Full Title: Influence of high dose vitamin D substitution on humoral immunity and lymphocyte function in patients with type 1 diabetes mellitus or Addison´s disease (ViDDA1)
    Medical condition: Type 1 diabetes mellitus or Addison´s disease (ViDDA1)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10001353 Adrenal gland disorders HLGT
    14.1 10014698 - Endocrine disorders 10012602 Diabetes mellitus (incl subtypes) HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000673-30 Sponsor Protocol Number: HAN-HCC-001 Start Date*: 2007-06-01
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Placebo kontrollierte Phase II Studie zur Therapie des fortgeschrittenen HCC mit Viscum fraxini
    Medical condition: Advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049010 Carcinoma hepatocellular LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000659-18 Sponsor Protocol Number: FumadermAA01 Start Date*: 2011-08-22
    Sponsor Name:University Hospital Tübingen
    Full Title: Treatment of therapy resistant Alopecia areata with fumaric acid esters (Fumaderm® and Fumaderm initial®) – an open, single center, non-randomized, pilot study with 40 patients
    Medical condition: Alopecia areata
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10001761 Alopecia areata PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022446-24 Sponsor Protocol Number: 2011-01 Start Date*: 2013-10-10
    Sponsor Name:Hospital of the Ludwig Maximilians University Munich
    Full Title: Active immunotherapy of patients with acute myeloid leukemia using autologous dendritic cells transfected with RNA encoding leukemia-associated antigens
    Medical condition: Male and female patients with AML of non-favorable risk profile not eligible for allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10000878 Acute myeloblastic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000962-14 Sponsor Protocol Number: CCM-RNT-202101 Start Date*: 2021-07-02
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001977-13 Sponsor Protocol Number: 020221 Start Date*: 2012-08-01
    Sponsor Name:Northwest Biotherapeutics Inc
    Full Title: A Phase III clinical trial evaluating DCVax®-L, autologous dendritic cells (DC) pulsed with tumor lysate antigen for the treatment of glioblastoma multiforme (GBM)
    Medical condition: Glioblastoma Multiforme
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003426-32 Sponsor Protocol Number: DCOne-002 Start Date*: 2017-12-11
    Sponsor Name:DCprime bv
    Full Title: AN INTERNATIONAL, MULTICENTRE, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DIFFERENT VACCINATION REGIMENS OF IMMUNOTHERAPY WITH ALLOGENEIC DENDRITIC CELLS, DCP-001, IN PATIENTS WIT...
    Medical condition: The medical condition investigated are patients with acute myeloid leukemia in complete remission with persistent minimal residual disease and as such are at high risk of relapse.
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) NO (Completed) SE (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023436-16 Sponsor Protocol Number: HOVON 107 Start Date*: 2011-05-31
    Sponsor Name:HOVON Foundation
    Full Title: The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: a randomized phase II study.
    Medical condition: stem cell mobilization
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053948 Hematopoietic stem cell mobilization LLT
    12.1 10024329 Leukemia LLT
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Restarted)
    Trial results: View results
    EudraCT Number: 2015-002685-23 Sponsor Protocol Number: ICT-107-301 Start Date*: 2016-08-19
    Sponsor Name:ImmunoCellular Therapeutics, Ltd.
    Full Title: A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy.
    Medical condition: Treatment of newly diagnosed glioblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018337 Glioblastoma multiforme PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) DE (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001325-24 Sponsor Protocol Number: SOV03 Start Date*: 2013-08-30
    Sponsor Name:SOTIO a.s.
    Full Title: A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy in women with relapsed platinum resistant epith...
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001323-38 Sponsor Protocol Number: SOV02 Start Date*: 2013-08-30
    Sponsor Name:SOTIO a.s.
    Full Title: A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with rel...
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 09:03:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA